Testing a new treatment for rheumatoid arthritis
2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis
This study is looking at how a new treatment called 2-hydroxybenzylamine (2-HOBA) can help people with rheumatoid arthritis by reducing inflammation and heart risks, and you'll either get the treatment or a placebo for 12 weeks to see how it works.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-10825562 on NIH RePORTER |
What this research studies
This research investigates the effects of a new compound called 2-hydroxybenzylamine (2-HOBA) on patients with rheumatoid arthritis (RA). The study aims to determine how well 2-HOBA can reduce inflammation and cardiovascular risks associated with RA by blocking harmful substances produced during oxidative stress. Patients will be randomly assigned to receive either 2-HOBA or a placebo for 12 weeks, allowing researchers to assess its safety and effectiveness. The approach is based on previous animal studies and early human trials that showed promise in reducing disease symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with rheumatoid arthritis who are experiencing inflammation and related cardiovascular risks.
Not a fit: Patients with rheumatoid arthritis who are not experiencing significant inflammation or cardiovascular issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that improves the health and quality of life for patients with rheumatoid arthritis.
How similar studies have performed: Previous studies have shown that similar approaches targeting oxidative stress in autoimmune conditions have been successful, making this research a promising continuation of that work.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Ormseth, Michelle Jane — Vanderbilt University Medical Center
- Study coordinator: Ormseth, Michelle Jane
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.